Analyzing COVID-19 progression with Markov multistage models: insights from a Korean cohort

利用马尔可夫多阶段模型分析COVID-19的进展:来自韩国队列研究的启示

阅读:1

Abstract

BACKGROUND: Understanding the progression and recovery process of COVID-19 is crucial for guiding public health strategies and developing targeted interventions. This longitudinal cohort study aims to elucidate the dynamics of COVID-19 severity progression and evaluate the impact of underlying health conditions on these transitions, providing critical insights for more effective disease management. METHODS: Data from 4549 COVID-19 patients admitted to Seoul National University Boramae Medical Center between February 5th, 2020, and October 30th, 2021, were analyzed using a 5-state continuous-time Markov multistate model. The model estimated instantaneous transition rates between different levels of COVID-19 severity, predicted probabilities of state transitions, and determined hazard ratios associated with underlying comorbidities. RESULTS: The analysis revealed that most patients stabilized in their initial state, with 72.2% of patients with moderate symptoms remaining moderate. Patients with hypertension had a 67.6% higher risk of progressing from moderate to severe, while those with diabetes had an 89.9% higher risk of deteriorating from severe to critical. Although transition rates to death were low early in hospitalization, these comorbidities significantly increased the likelihood of worsening conditions. CONCLUSION: This study highlights the utility of continuous-time Markov multistate models in assessing COVID-19 severity progression among hospitalized patients. The findings indicate that patients are more likely to recover than to experience worsening conditions. However, hypertension and diabetes significantly increase the risk of severe outcomes, underscoring the importance of managing these conditions in COVID-19 patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。